Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dayong Zhai

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Chemistry & Biology|May 5, 2004
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)Barbara Becattini, Shinichi Kitada, Marilisa Leone, et al.
The Journal of Biological Chemistry|December 22, 2009
Vaccinia virus protein F1L is a caspase-9 inhibitorDayong Zhai, Eric Yu, Chaofang Jin, et al.
Nature Protocols|July 2, 2011
Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry, using six Bcl-2 family proteins as examplesPeter C Simons, Susan M Young, Mark B Carter, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
Inhibition of Bfl-1 with N-aryl maleimidesJohn R Cashman, Mary MacDonald, Senait Ghirmai, et al.
Cancer Letters|September 11, 2008
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonistsJun Wei, Michele F Rega, Shinichi Kitada, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2006
Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting BidBarbara Becattini, Carsten Culmsee, Marilisa Leone, et al.
Journal of Medicinal Chemistry|May 6, 2010
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic interventionAnton V Cheltsov, Mika Aoyagi, Alexander Aleshin, et al.
Molecular Cancer Therapeutics|June 23, 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant MutationsBrion W Murray, Dayong Zhai, Wei Deng, et al.
Journal of Medicinal Chemistry|June 27, 2009
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteinsJun Wei, Shinichi Kitada, Michele F Rega, et al.
Journal of Medicinal Chemistry|November 2, 2010
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteinsJun Wei, Shinichi Kitada, John L Stebbins, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Chemistry & Biology|May 5, 2004
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)Barbara Becattini, Shinichi Kitada, Marilisa Leone, et al.
The Journal of Biological Chemistry|December 22, 2009
Vaccinia virus protein F1L is a caspase-9 inhibitorDayong Zhai, Eric Yu, Chaofang Jin, et al.
Nature Protocols|July 2, 2011
Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry, using six Bcl-2 family proteins as examplesPeter C Simons, Susan M Young, Mark B Carter, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
Inhibition of Bfl-1 with N-aryl maleimidesJohn R Cashman, Mary MacDonald, Senait Ghirmai, et al.
Cancer Letters|September 11, 2008
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonistsJun Wei, Michele F Rega, Shinichi Kitada, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2006
Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting BidBarbara Becattini, Carsten Culmsee, Marilisa Leone, et al.
Journal of Medicinal Chemistry|May 6, 2010
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic interventionAnton V Cheltsov, Mika Aoyagi, Alexander Aleshin, et al.
Molecular Cancer Therapeutics|June 23, 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant MutationsBrion W Murray, Dayong Zhai, Wei Deng, et al.
Journal of Medicinal Chemistry|June 27, 2009
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteinsJun Wei, Shinichi Kitada, Michele F Rega, et al.
Journal of Medicinal Chemistry|November 2, 2010
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteinsJun Wei, Shinichi Kitada, John L Stebbins, et al.
Pageof 5